Editas Medicine stock holds the line as pipeline work continues.
Editas Medicine remains focused on its gene-editing pipeline and Nasdaq listing, emphasizing clinical progress and regulatory milestones. As a clinical-stage company, its value is tied to development updates and balance-sheet durability, rather than immediate sales. Investors monitor funding needs and study timelines, with each update being crucial for the company's advancement through decision points.
Editas Medicine, Inc.(NasdaqGS:EDIT) added to Russell Small Cap Comp Growth Benchmark
Editas Medicine, Inc. (NasdaqGS:EDIT) has been added to the Russell Small Cap Comp Growth Benchmark. The company, a genome-editing firm, is engaged in developing genomic medicines using CRISPR technology to treat various serious diseases. This inclusion highlights its growing recognition in the financial markets and follows several recent announcements regarding its preclinical data and public offerings.
Editas Medicine, Inc.(NasdaqGS: EDIT) added to Russell 2500 Growth Benchmark
Editas Medicine, Inc. (NasdaqGS: EDIT) has been added to the Russell 2500 Growth Benchmark. This news follows a series of recent announcements, including the company's inclusion in several other Russell benchmarks and updates on its preclinical data for EDIT-401 for hyperlipidemia. Editas Medicine, a genome-editing company, focuses on developing genomic medicines using CRISPR technology for various serious diseases.
Editas Medicine, Inc.(NasdaqGS: EDIT) added to Russell Microcap Growth Benchmark Index
Editas Medicine, Inc. (NasdaqGS: EDIT) has been added to the Russell Microcap Growth Benchmark Index as of June 28, 2026. This inclusion is among several other Russell index additions for the company, including the Russell Small Cap Comp Growth, Russell 2500 Growth, Russell 2000 Growth, and Russell 3000 Growth indices. The genome-editing company continues to make progress with its preclinical studies, particularly for EDIT-401, which is being developed as a potential treatment for hyperlipidemia.
Editas Medicine, Inc.(NasdaqGS: EDIT) added to Russell 2000 Growth Benchmark
Editas Medicine, Inc. (NasdaqGS: EDIT) has been added to the Russell 2000 Growth Benchmark, a significant inclusion for the genome-editing company. This news, published on June 29, 2026, also notes its addition to the Russell Small Cap Comp Growth Benchmark and Russell 2500 Growth Benchmark. The company specializes in developing genomic medicines using proprietary CRISPR technology.
Price to sales forward of Editas Medicine, Inc. – NASDAQ:EDIT
This article provides financial information for Editas Medicine, Inc. (NASDAQ: EDIT), specifically focusing on its forward price-to-sales ratio. It details where the data is sourced from, including ICE Data Services and FactSet, and notes that the information is provided by TradingView.
Enterprise value to EBITDA forward of Editas Medicine, Inc. – NASDAQ:EDIT
This article displays the forward Enterprise Value to EBITDA for Editas Medicine, Inc. (NASDAQ: EDIT). It presents basic financial and market information related to the company, indicating that the market was closed at the time of the data display. The page is sourced from TradingView, providing an overview of EDIT's financials.
Price to earnings forward of Editas Medicine, Inc. – LSE:0IFK
This article provides financial information for Editas Medicine, Inc. (LSE:0IFK), specifically focusing on its forward price-to-earnings ratio. The content appears to be a stub or a data point from a financial platform, showing the company's identifier on the London Stock Exchange and indicating a market closed status with no trades.
Price to book forward of Editas Medicine, Inc. – NASDAQ:EDIT
This article displays the "Price to book forward" financial metric for Editas Medicine, Inc. (NASDAQ: EDIT). It presents a value for a specific period and notes any changes in that value, but does not provide additional details or analysis. The content appears to be a stub or a data point from a financial platform.
Enterprise value to EBITDA forward of Editas Medicine, Inc. – LSE:0IFK
This article provides financial information for Editas Medicine, Inc. (LSE:0IFK), specifically focusing on its Enterprise Value to EBITDA (EV/EBITDA) forward metric. It appears to be a financial data page from TradingView, displaying market status and a link to detailed financial data.
Editas Medicine, Inc. Actuals & Estimates (NASDAQ:EDIT)
This article provides an overview of Editas Medicine, Inc. (NASDAQ: EDIT) financial actuals and estimates, stock performance, and analyst forecasts. It details historical stock prices, market capitalization, volatility, and upcoming earnings reports, along with other financial statistics like revenue and net income. The piece also includes answers to frequently asked questions regarding EDIT's stock ticker, price movements, and how to invest.
Editas Medicine, Inc. Actuals & Estimates (FWB:8EM)
This article provides an overview of Editas Medicine, Inc.'s financial data and analyst estimates, including income statement, balance sheet, and cash flow. It also covers analyst price forecasts, historical stock prices, upcoming earnings dates, and quarterly financial results such as EPS, revenue, and net income.
Editas Medicine, Inc. Actuals & Estimates (LSE:0IFK)
This article provides an overview of Editas Medicine, Inc. (LSE:0IFK) stock, including its current price, market capitalization, and historical performance. It also details financial actuals and estimates, analysts' price targets, and key financial metrics like earnings, revenue, and EBITDA. The report indicates that the company does not pay dividends and outlines upcoming earnings report dates.
EDIT Forecast — Price Target — Prediction for 2027
This article provides a forecast for Editas Medicine, Inc. (EDIT) stock, including analyst price targets, past performance, and key financial metrics. It highlights the stock's current price, market capitalization, and upcoming earnings report, while also addressing frequently asked questions about its volatility and dividend policy.
Editas Medicine | 4: Statement of changes in beneficial ownership of securities-Director Hirsch Andrew
This document is a Form 4 filing for Editas Medicine, detailing changes in beneficial ownership of securities for Director Andrew Hirsch. Such filings are made with the SEC to report transactions by company insiders.
Editas Medicine | 4: Statement of changes in beneficial ownership of securities-Director Hopfield Jessica
This article provides a Form 4 statement for Editas Medicine, detailing changes in beneficial ownership of securities for Director Jessica Hopfield. The document reports on transactions that have altered her holdings in the company.
Editas Medicine (EDIT) director awarded 51,700 stock options at $2.55 strike
Editas Medicine, Inc. director David Scadden was granted 51,700 stock options with an exercise price of $2.55 per share, set to expire on June 16, 2036. The options were granted on June 17, 2026, and will vest in full on June 17, 2027. This transaction is a compensation-related award rather than a market purchase or sale.
Editas Medicine (NASDAQ: EDIT) director granted 51,700 stock options at $2.55
Editas Medicine director Jessica Hopfield was granted 51,700 stock options at an exercise price of $2.55 per share on June 17, 2026. These options are scheduled to vest in full on June 17, 2027, and will expire on June 16, 2036. This transaction was reported in a Form 4 filing and represents a compensation-related award rather than an open-market purchase or sale.
Editas Medicine (EDIT) director Andrew Hirsch awarded 51,700 stock options
Editas Medicine director Andrew Hirsch was granted 51,700 stock options with an exercise price of $2.55 per share. These options, granted on June 17, 2026, are scheduled to fully vest on June 17, 2027, and expire on June 16, 2036. This grant serves as a compensation award, and no open-market stock transactions were reported in the filing.
[Form 4] Editas Medicine, Inc. Insider Trading Activity
Editas Medicine, Inc. director Bernadette Connaughton received a grant of 51,700 stock options with an exercise price of $2.55 per share, vesting fully on June 17, 2027, and expiring on June 16, 2036. This transaction is considered neutral in sentiment and filing impact, with no open-market buys or sells reported. Following the grant, Connaughton now holds 51,700 derivative securities directly.
Form 4 Editas Medicine For: 22 June By Investing.com
This article from Investing.com is a straightforward financial market update, primarily serving as a placeholder for a "Form 4" filing for Editas Medicine (EDIT) dated June 22. It briefly mentions the stock's performance on that day, showing a 4.09% increase. The content also includes extensive financial market data, indices, commodity prices, and other related news snippets.
Editas Medicine (EDIT) director granted 51,700 stock options at $2.55 strike
Editas Medicine director Elliott M. Levy was granted 51,700 stock options with an exercise price of $2.55 per share on June 17, 2026. These options are scheduled to vest in full on June 17, 2027, and will expire on June 16, 2036. Following this grant, Levy holds 51,700 derivative securities directly.
Editas Medicine elects two directors and ratifies auditor at annual meeting
Editas Medicine (NASDAQ:EDIT) held its 2026 Annual Meeting where shareholders elected Bernadette Connaughton and Elliott Levy as Class I directors and approved executive compensation on an advisory basis. Shareholders also ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2026. The company, with a market cap of $411 million, is navigating financial challenges with a negative gross profit margin.
Editas Medicine elects two directors and ratifies auditor at annual meeting
Editas Medicine held its 2026 Annual Meeting where shareholders elected Bernadette Connaughton and Elliott Levy, M.D., as Class I directors. They also approved the compensation for executive officers and ratified PricewaterhouseCoopers LLP as their independent registered public accounting firm. The company, which reported $38.69 million in revenue, is trading at $2.68 per share, with InvestingPro analysis indicating it is overvalued.
Editas Medicine (NASDAQ: EDIT) stockholders elect directors and ratify PwC at 2026 meeting
Editas Medicine (EDIT) held its 2026 annual stockholder meeting where investors elected Bernadette Connaughton and Elliott Levy, M.D. as Class I directors to serve until the 2029 annual meeting. Stockholders also approved, on an advisory basis, the compensation of the company's named executive officers and ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. These decisions address key governance matters including board composition, executive pay, and auditor selection.
Editas Medicine Inc (EDIT) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Editas Medicine Inc's (EDIT) dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years and has no record of stock splits. The page also displays current stock information such as price and market cap.
Editas Medicine Inc (EDIT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article from TradingKey attempts to provide a revenue breakdown for Editas Medicine Inc (EDIT), including business segments, regional revenue, and profit contribution. However, the company has not disclosed the relevant financial data, resulting in no information being available for these sections. The article indicates that users can add EDIT to a watchlist and view general company information, but specific revenue details are absent.
COMMODORE CAPITAL LP Acquires Significant Stake in Editas Medicine Inc
COMMODORE CAPITAL LP has acquired a significant 9.90% stake in Editas Medicine Inc, purchasing 16,045,802 shares at $3.08 each. This strategic investment, valued at $1.73 billion, integrates Editas Medicine, a clinical-stage biotechnology company focused on CRISPR technology, into COMMODORE CAPITAL LP's portfolio, enhancing its presence in the healthcare sector. Despite Editas Medicine Inc's current financial challenges, including an "overvalued" stock rating and low GF-Score, the acquisition underscores COMMODORE CAPITAL LP's commitment to genomic medicine and could provide crucial support for Editas's advancement in gene editing.
RA CAPITAL MANAGEMENT, L.P. Acquires Significant Stake in Editas Medicine Inc
RA CAPITAL MANAGEMENT, L.P. has acquired 8,889,000 shares of Editas Medicine Inc for $3.57 per share, making it a new holding and a 5.80% position in the biotechnology firm's portfolio. This strategic investment, impacting the firm's portfolio by 0.34%, highlights a continued interest in genome editing technology despite Editas Medicine Inc's current overvaluation and financial challenges. Editas Medicine Inc, a USA-based company specializing in CRISPR technology, faces volatility with its stock price at $2.71, yet shows revenue and EBITDA growth.
Editas Medicine (EDIT) CEO logs automatic, tax-related share sale
Editas Medicine's CEO, O'Neill Gilmore Neil, reported an automatic sale of 15,380 shares of common stock at a weighted average price of $2.7011 per share on June 3, 2026. This transaction was not discretionary but was executed under a pre-established plan to cover tax withholding obligations from restricted stock units that vested on June 2, 2026. Following the sale, the CEO directly owns 248,313 shares.
Editas Medicine (EDIT) CSO sells 731 shares under automatic tax-cover plan
Linda Burkly, EVP, Chief Scientific Officer of Editas Medicine (EDIT), sold 731 shares worth $1,975 on June 3, 2026, at a weighted average price of $2.7011 per share. This sale was a non-discretionary transaction executed under an automatic sales instruction plan adopted on July 3, 2023, to cover tax withholding obligations from restricted stock units that vested on June 2, 2026. Following the transaction, Burkly directly holds 67,297 shares of Editas Medicine common stock.
Editas Medicine (EDIT) CFO logs small automatic tax-related share sale
Editas Medicine's CFO, Amy Parison, sold 464 shares of common stock at a weighted average price of $2.7010 per share on June 3, 2026. This sale was conducted under a pre-established automatic plan to cover tax withholding obligations from vested restricted stock units and was not a discretionary trade. Following the transaction, she directly holds 14,970 shares of Editas Medicine common stock.
Editas Medicine CFO Amy Parison sells $1,253 in stock
Editas Medicine CFO Amy Parison sold 464 shares of company common stock worth $1,253 on June 3, 2026. This transaction was executed to cover tax withholding obligations associated with restricted stock unit vesting and was part of a pre-established automatic sales plan. Following the sale, Ms. Parison directly holds 14,970 shares, while the company's stock has seen a recent decline but remains up year-to-date.
Editas Medicine CEO Gilmore O’Neill sells $41,542 in stock
Editas Medicine CEO Gilmore O’Neill sold 15,380 shares of common stock for $41,542 on June 3, 2026. This sale was not a discretionary trade but rather to cover tax withholding obligations from vested restricted stock units. Despite a recent 14% stock decline, shares are up 66% over the last year, and the stock is considered undervalued by InvestingPro analysis.
EDIT: EDIT-401 shows durable 90% LDL and Lp(a) reduction, with clinical trials starting in 2024
A new CRISPR-based therapy, EDIT-401 by Editas Medicine, Inc., has shown promising results in preclinical studies, achieving 90% reductions in LDL cholesterol and Lp(a). Clinical trials for this therapy, aimed at high-risk cardiovascular patients, are slated to begin in Australia in 2024, with initial data expected in 2027.
Why Is Editas (EDIT) Down 12.4% Since Last Earnings Report?
Editas Medicine (EDIT) shares have dropped 12.4% since its last earnings report, underperforming the S&P 500. The company reported a narrower-than-expected Q1 2026 loss of 26 cents per share, driven by lower operating expenses, though revenues declined year-over-year. Analysts have shown an upward trend in estimates since the earnings release, and the stock currently holds a Zacks Rank #3 (Hold).
TCG Crossover group reports 9.9% stake in Editas Medicine (EDIT) after offering
TCG Crossover Fund III entities, along with Chen Yu, have reported a 9.9% beneficial ownership stake in Editas Medicine (EDIT) through a Schedule 13G filing. This ownership comprises 15,798,999 shares, including both issued common stock and shares from warrants exercisable within 60 days. The filing details how a "Beneficial Ownership Limitation" prevents the exercise of additional warrants to keep the stake below 9.99%.
RA Capital affiliates report 8.89M shares in Editas Medicine (EDIT)
RA Capital Management, L.P. and its affiliates, including Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P., have reported a shared beneficial ownership of 8,889,000 shares of Editas Medicine common stock. This stake represents 5.8% of the company's outstanding shares as of May 27, 2026. The filing explicitly states that the reporting persons disclaim group status and beneficial ownership except for Section 13(d) purposes, with RA Capital delegated sole voting and dispositive power over the shares held by the Fund.
EDIT - Editas Medicine Inc Stock Price and Quote
This article provides a detailed overview of Editas Medicine Inc. (EDIT) stock, including its current price, financial metrics, performance indicators, and recent news and analyst ratings. It also lists insider trading activities and key personnel within the company.
Commodore reports 16.05M-share position in Editas Medicine (EDIT) under 9.99% cap
Commodore Capital entities have reported a 16.05 million-share position in Editas Medicine (EDIT) through a Schedule 13G filing. This includes 8.89 million common shares and 7.16 million warrant-linked shares, with beneficial ownership capped at 9.99% for warrant exercises. The filing underscores a large passive stake by Commodore Capital LP, Commodore Capital Master LP, Robert Egen Atkinson, and Michael Kramarz.
Editas Medicine Inc stock (US28106W1036): Q1 2026 loss narrows as Nasdaq-listed gene-editing player gains momentum
Editas Medicine (EDIT) reported a narrower loss of USD 0.26 per share in Q1 2026, indicating improved cost management and potential revenue contributions. The Nasdaq-listed stock has seen a significant rebound, gaining 58.35% over the past month, despite a 41.47% year-on-year decline, attracting renewed investor attention in the biotech sector. The company's focus on CRISPR-based gene-editing therapies and upcoming clinical milestones are central to its future market trajectory.
EDIT (NASDAQ) insider notice: 15,000-share resale; 32,957 RSUs vested
An insider at Editas Medicine, Inc. (EDIT) has filed a Form 144, indicating a proposed resale of 15,000 shares of common stock valued at $46,200, effective June 3, 2026. The filing also reports the vesting of 32,957 Restricted Stock Units (RSUs) on June 2, 2026, and a prior sale of 5,394 shares for $10,894.26 on March 3, 2026. This notice is a declaration of intent and not a confirmation of sale.
Gene editing firm Editas to webcast Jefferies talk June 4 live
Editas Medicine (Nasdaq: EDIT) announced an updated presentation time for its appearance at the 2026 Jefferies Global Healthcare Conference. The gene-editing company will now present on June 4, 2026, at 2:00 p.m. ET in New York. A live webcast and a 30-day replay will be available via its investor website.
Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference
Editas Medicine, Inc. announced an updated presentation time for their participation in the 2026 Jefferies Global Healthcare Conference. The gene editing company will now present on Thursday, June 4, 2026, at 2:00 p.m. ET. A live webcast and an archived replay will be available on the Investors section of their company website.
Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference
Editas Medicine announced an updated presentation time for the 2026 Jefferies Global Healthcare Conference. The company will now present on Thursday, June 4, 2026, at 2:00 p.m. ET. A live webcast and archived replay of the presentation will be available on the company's website.
Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference
Editas Medicine announced an updated presentation time for its appearance at the 2026 Jefferies Global Healthcare Conference. The company will now present on Thursday, June 4, 2026, at 2:00 p.m. ET. A live webcast of the presentation will be available on the company's website, with an archived replay available for approximately 30 days afterward.
Editas Medicine: Resetting Pipeline Just To Be Second To Market Again (NASDAQ:EDIT)
Editas Medicine has refocused its pipeline, discontinuing ex vivo gene editing programs to concentrate solely on in vivo CRISPR therapy, particularly EDIT-401 for severe hyperlipidemia. The company faces significant execution and competitive risks, as EDIT-401 is still in preclinical stages and the commercial viability of a high-cost, one-time treatment faces hurdles with insurers. While cash reserves are projected to last into Q3 2027, this is contingent on milestone payments from Vertex, and the stock is rated a "hold" due to these uncertainties despite its current price appearing risk-adjusted fair.
Q2 EPS Estimates for Editas Medicine Raised by HC Wainwright
HC Wainwright has revised its Q2 2026 EPS estimates for Editas Medicine, raising it to -$0.32 from -$0.34, although the company is still projected to operate at a loss. Despite ongoing dilution from financing activities like public offerings, analyst sentiment remains a "Moderate Buy" with a target price of $5.40, driven by promising preclinical data for EDIT-401 and anticipated clinical milestones in 2026. Editas Medicine, a clinical-stage biotechnology company, focuses on gene-editing therapies for genetic diseases, with key pipeline programs like EDIT-101 and EDIT-301.
Analysts Issue Forecasts for Editas Medicine Q2 Earnings
Zacks Research has updated its Q2 2026 EPS estimate for Editas Medicine to ($0.32), indicating a slight improvement but still forecasting losses. The biotech company holds a "Moderate Buy" consensus rating with a $5.40 price target, driven by positive preclinical results for EDIT-401, despite recent share dilution from a public offering. Institutional investors have significantly increased their holdings in Editas Medicine, with Renaissance Technologies LLC and UBS AM among those boosting stakes.
Editas Medicine stock dips on proposed equity offering
Editas Medicine's stock experienced a decline following the announcement of a proposed public offering of its common stock. The biopharmaceutical company intends to use the net proceeds from this offering for general corporate purposes, including funding research and development for its EDIT-301 program and other pipeline candidates, as well as for working capital and other corporate expenses. The offering will be underwritten, and the announcement has led to a decrease in investor confidence, impacting the stock price.
